Description: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Home Page: immunovant.com
IMVT Technical Analysis
320 West 37th Street
New York,
NY
10018
United States
Phone:
917 580 3099
Officers
| Name | Title |
|---|---|
| Dr. Frank M. Torti M.B.A., M.D., MBA | Exec. Chairperson of the Board |
| Dr. Peter Salzmann M.B.A., M.D. | CEO & Director |
| Ms. Eva Renee Barnett M.B.A. | Chief Financial Officer |
| Dr. William L. Macias M.D., Ph.D. | Chief Medical Officer |
| Dr. Julia G. Butchko Ph.D. | Chief Devel. & Technology Officer |
| Dr. Chau Cheng M.B.A., Ph.D. | VP of Investor Relations |
| Mr. Mark S. Levine | Chief Legal Officer & Corp. Sec. |
| Ms. Lauren Schrier M.B.A. | VP of Marketing |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.7266 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-06-21 |
| Fiscal Year End: | March |
| Full Time Employees: | 124 |